Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

28.7K
Overview
28.7K
Allergic Reactions02:06

Allergic Reactions

26.4K
Overview
26.4K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Hypersensitivities01:30

Hypersensitivities

7.3K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
7.3K
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

280
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
280

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Algorithms in allergy: An algorithm for alpha-Gal syndrome diagnosis and treatment, 2024 update.

Allergy·2024
Same author

Does a strong IgG response precede allergic sensitization?

Allergy·2018
Same author

Meat allergy associated with galactosyl-α-(1,3)-galactose (α-Gal)-Closing diagnostic gaps by anti-α-Gal IgE immune profiling.

Allergy·2017
Same author

Serological, genomic and structural analyses of the major mite allergen Der p 23.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2015
Same author

Analysis of cytokine production by peanut-reactive T cells identifies residual Th2 effectors in highly allergic children who received peanut oral immunotherapy.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2015
Same author

Desensitization treatment for hay fever.

Immunology today·2014
Same journal

Tamoxifen-driven neutrophil reprogramming protects from pulmonary Granulibacter bethesdensis infection in chronic granulomatous disease.

The Journal of allergy and clinical immunology·2026
Same journal

Clinical and transcriptomic characterization of mixed granulocytic COPD phenotype.

The Journal of allergy and clinical immunology·2026
Same journal

Dupilumab outcomes in pediatric asthma by early eosinophil status: post hoc analysis of VOYAGE/EXCURSION.

The Journal of allergy and clinical immunology·2026
Same journal

Maternal antibiotic exposure alters the newborn metabolomic profile and increases the risk of respiratory infections in offspring: a 13-year longitudinal birth cohort study.

The Journal of allergy and clinical immunology·2026
Same journal

Selective Elimination of Mast Cells via Siglec-6-Targeted Nanodelivery of Drug Payload.

The Journal of allergy and clinical immunology·2026
Same journal

Loss of epidermal miR-149 sensitizes to skin inflammation.

The Journal of allergy and clinical immunology·2026
See all related articles

Related Experiment Video

Updated: May 3, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

22.5K

Future directions for allergen immunotherapy

T A Platts-Mills1, G A Mueller, L M Wheatley

  • 1Asthma & Allergic Diseases Center, University of Virginia, Charlottesville 22908, USA.

The Journal of Allergy and Clinical Immunology
|October 13, 1998
PubMed
Summary
This summary is machine-generated.

Advancements in understanding allergic disease and immunotherapy are paving the way for novel treatments. Researchers are exploring recombinant allergens and gene-based therapies to precisely target immune responses for better allergy management.

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

11.3K
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.9K

Related Experiment Videos

Last Updated: May 3, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

22.5K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

11.3K
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.9K

Area of Science:

  • Immunology
  • Allergy Research
  • Biotechnology

Background:

  • Traditional immunotherapy regimens for allergic diseases have remained largely unchanged for decades.
  • Recent scientific progress has significantly enhanced our understanding of allergic disease mechanisms.
  • New technologies allow for precise monitoring and targeting of immune system components.

Purpose of the Study:

  • To review advancements in immunotherapy for allergic diseases.
  • To explore novel approaches utilizing recombinant DNA technology and genetic engineering.
  • To discuss the potential of new adjuvants and targeted T-cell modulation.

Main Methods:

  • Utilizing recombinant DNA technology to produce modified allergens.
  • Employing site-directed mutagenesis to alter allergen-IgE binding while preserving T-cell recognition.
  • Investigating plasmid-based gene delivery systems for controlled allergen expression and immune response modulation.
  • Exploring the use of novel adjuvants like IL-12 and immunostimulatory DNA sequences.

Main Results:

  • Recombinant allergens can be engineered to reduce IgE reactivity while maintaining T-cell responses.
  • Gene-based approaches offer control over allergen expression and immune response profiles (cytokine, antibody isotype).
  • Advanced understanding of immune cells involved in allergic responses enables targeted treatment design.

Conclusions:

  • Modern biotechnology offers powerful tools for developing next-generation allergy immunotherapies.
  • Targeting specific immune pathways and utilizing engineered allergens holds promise for effective allergy treatment.
  • Translating current scientific knowledge into clinical practice remains a key challenge for allergy management.